Piper Jaffray Starts BridgeBio Pharma (BBIO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
SVB Leerink Starts BridgeBio Pharma (BBIO) at Outperform
July 22, 2019 6:17 AM EDTSVB Leerink initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating and a price target of $34.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
... MoreJPMorgan Starts BridgeBio Pharma (BBIO) at Overweight
July 22, 2019 4:25 AM EDTJPMorgan initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Overweight rating and a price target of $38.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
... MoreJefferies Starts BridgeBio Pharma (BBIO) at Buy
July 22, 2019 3:58 AM EDTJefferies analyst Eun Yang initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Buy rating and a price target of $38.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
... MoreGoldman Sachs Starts BridgeBio Pharma (BBIO) at Buy
July 22, 2019 2:28 AM EDTGoldman Sachs analyst Paul Choi initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Buy rating and a price target of $42.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
... MoreBMO Capital Starts BridgeBio Pharma (BBIO) at Outperform
July 22, 2019 1:57 AM EDTBMO Capital analyst George Farmer initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating and a price target of $49.00.
The analyst comments "We believe BridgeBio's platform of 16 products in preclinical and clinical development offers a compelling opportunity for investors looking for prudent... More
